Tirzepatide — compounding legality overview

Dual GLP-1/GIP compounding rules

Common names: Mounjaro, Zepbound

PeptSense tracks Tirzepatide across federal 503A Bulks List chain steps, PCAC advisory context, and state board positions. Status is never inferred from forums or marketing sites — only published citations with effective dates.

Federal 503A snapshot (illustrative)

Latest published federal event for 503A compounding pharmacies. Sign in for your licensed states and facility type.

Summary

Honest curation baseline (2026-08-01): Tirzepatide is a component of FDA-approved products. Compounding as an essentially copy of an approved drug is generally restricted under 503A when commercial product is available (shortage exceptions are fact-specific). Confirm shortage status and counsel. Not a legal determination.

Citation

FDA — essentially copies of approved drugs (503A)

Effective

Aug. 1, 2026

Not a legal determination. Replace placeholder citations during curation.

Run a full lookup

Get federal + state lanes, chain steps, printable answer cards, and compliance documents for the states you license in.